PRIC: Application of PREVENA in Reducing Surgical Site Complications Following Reversal of Ileostomy or Colostomy

Sponsor
St. James's Hospital, Ireland (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT04974931
Collaborator
(none)
50
1
2
5.9
8.4

Study Details

Study Description

Brief Summary

Surgical site infections (SSI) remain one of the most common complications associated with reversal of ileostomy and colostomy. In addition to having detrimental impacts on the patient's post-operative course, they also pose significant financial ramifications.

There have been comparative studies in the use of negative pressure wound therapy in reducing surgical site infections.

PREVENA Incision Management System is a type of disposable, customizable and powered negative pressure system designed to help manage and protect surgical incisions and their surrounding environment. It is now commonly used as a surgical wound dressings in the setting of vascular surgeries, post-cesarean infections and colorectal resections.

Our study is designed as a randomised controlled trial to examine if PREVERA therapy as a NPWT is more superior than conventional dressings in reducing the rate of surgical site infections.

Condition or Disease Intervention/Treatment Phase
  • Device: PREVENA Incision Management System
N/A

Detailed Description

Background:

Surgical site infections (SSI) remain one of the most common complications associated with reversal of ileostomy. In addition to having detrimental impacts on the patient's post-operative course, they also pose significant financial ramifications.

The use of Negative Pressure Wound Therapy (NPWT) is one strategy that has been extensively studied in reducing the rate of surgical site infections.

PREVENA Therapy is a form of Incisional Negative Pressure Wound Therapy (INPWT) that has been widely used in the management of closed surgical incisions. They are delivered as prophylactic measures in preventing surgical complications such as surgical site infections.

Trial Design:

This study is designed as a randomized, controlled, open-label, multi-center superiority trial with 2 parallel groups and primary endpoint of surgical site infection at day 7 (after 7-day use of PREVENA) and day 30.

Study Setting The trial will be conducted at two different hospitals located in Dublin, Ireland: St James Hospital - Ireland's largest acute academic teaching hospital (Academic Partner - Trinity College Dublin); Tallaght University Hospital - (Academic Partner - Trinity College Dublin)

Study Design

Study Type:
Interventional
Anticipated Enrollment :
50 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
Randomized, controlled, open-label, multi-center superiority trial with 2 parallel groups and primary endpoint of surgical site infection at day 7 (after 7-day use of PREVENA) and day 30.Randomized, controlled, open-label, multi-center superiority trial with 2 parallel groups and primary endpoint of surgical site infection at day 7 (after 7-day use of PREVENA) and day 30.
Masking:
None (Open Label)
Primary Purpose:
Prevention
Official Title:
Application of PREVENA (Surgical Incision Protection System) in Reducing Surgical Site Complications Following Reversal of Ileostomy or Colostomy: A Randomized Controlled Trial (PRIC Trial)
Anticipated Study Start Date :
Nov 1, 2021
Anticipated Primary Completion Date :
Apr 1, 2022
Anticipated Study Completion Date :
May 1, 2022

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: Patients applied with PREVENA system

This arm relates to the group of participants applied with PREVANA system post reversal of colostomy/ileostomy.

Device: PREVENA Incision Management System
Eligible participants, i.e. participants meeting inclusive criteria, will be randomised in equal proportions and divided into two arms. The PREVENA dressings will be applied to the
Other Names:
  • PREVENA Negative Pressure System
  • No Intervention: Patients applied with conventional dressings

    This arm relates to the group of participants applied with conventional dressings post reversal of colostomy/ileostomy

    Outcome Measures

    Primary Outcome Measures

    1. To measure surgical site infection incidence on outpatient follow up post reversal ileostomy/colostomy [Four to Six weeks]

      The investigators will be assessing and measuring the incidence of surgical site incidence on follow up appointments

    Secondary Outcome Measures

    1. To measure surgical site infection incidence on day 5 post reversal ileostomy/colostomy (or earlier, if deemed fit for discharge prior to day 5) [Five days post reversal ileostomy/colostomy]

      The investigators will be assessing and measuring the incidence of surgical site incidence on day 5 post reversal ileostomy/colostomy

    2. To measure the time to wound healing [One to Four weeks]

      The investigators will be assessing and measuring the time to wound healing based on the duration and last appointment date of home visits by public healthcare nurses involving wound care management

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Patients aged over 18 years old

    • Patients undergoing elective reversal of ileostomy/colostomy

    • Patients who agree to consent to inclusion and follow-up protocol

    Exclusion Criteria:
    • Patients who do not fulfil study protocol

    • Dressings being removed outside defined time periods

    • Patients who do not attend for regular outpatient follow up appointments

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 St James's Hospital Dublin Ireland D08 NHY1

    Sponsors and Collaborators

    • St. James's Hospital, Ireland

    Investigators

    None specified.

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Michael Kelly, Consultant Colorectal Surgeon, St. James's Hospital, Ireland
    ClinicalTrials.gov Identifier:
    NCT04974931
    Other Study ID Numbers:
    • St James Hospital
    First Posted:
    Jul 23, 2021
    Last Update Posted:
    Sep 21, 2021
    Last Verified:
    Sep 1, 2021
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No

    Study Results

    No Results Posted as of Sep 21, 2021